Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a developer of advanced vision restoration technologies, announced that debentureholders have converted $1.4 million of their principal into common shares at a price of $0.32 per share, resulting in the issuance of 4,375,000 common shares. The conversion represents 35% of the company’s previously outstanding debenture principal of $4 million, significantly strengthening its balance sheet as it approaches key milestones in its patient study program.
“These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision,” said Dean Burns, President and CEO of Ocumetics. “We are actively managing our investments and stakeholder relationships as we continue to advance our patient study and focus on achieving the next major milestones for the Company.”
The conversion of debt into equity is expected to improve the company’s financial flexibility and reduce ongoing interest costs while aligning investor interests with the continued advancement of Ocumetics’ technology platform and clinical development objectives. This move comes as Ocumetics prepares for its planned Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration, a critical regulatory milestone for its dynamic intraocular lens technology.
Ocumetics is currently in the first-in-human early feasibility study phase of its game-changing technology for the ophthalmic industry. The company has developed a dynamic intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The lens is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses and without perceptible time lag.
This debt conversion not only strengthens Ocumetics’ balance sheet but also signals strong investor confidence as the company navigates the complex regulatory pathway required to bring its technology to market. The reduction in debt and associated interest costs could provide the company with greater financial runway to complete its early feasibility study and prepare for the IDE submission. For the ophthalmic industry, Ocumetics’ technology represents a potential paradigm shift in vision correction, moving beyond traditional intraocular lenses that provide only fixed focus.
The company’s focus on advancing its patient study and achieving regulatory milestones underscores the importance of this financial restructuring. By converting debt to equity, Ocumetics aligns its capital structure with the long-term goals of its clinical program, potentially reducing financial risk for the company as it seeks FDA approval. The outcome of these efforts could have significant implications for patients who currently rely on glasses or contact lenses, offering a novel solution that leverages the eye’s natural biomechanics.
